This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
Vivian Xie
22 Aug 2022

$475 million acquisition of Metrics Contract Services by Catalent Inc.

Catalent Inc. is set to acquire Metrics Contract Services in a USD $475 million bid to expand its high-potent capacities and oral development and manufacturing capabilities by the end of 2022

Drug and healthcare solutions provider Catalent Inc. have announced their plans to acquire full-service CDMO Metrics Contract Services to bolster its capabilities for integrated oral solid formulation development, manufacturing, and packaging.

The USD $475 million acquisition, which includes a facility in Greenville, North Carolina to join Catalent’s headquarters in Somerset, New Jersey, will also expand Catalent’s capacity in handling high-potent compounds. The Greenville facility expands over 333,000 square-feet and is designed with comprehensive acceleration and development capabilities for early drug development through to commercial launch programs. With over USD $100 million in improvements over the last 5 years and 16 manufacturing suites, 11 of which are designed to handle highly potent compounds, the facility's annual production capacity is estimated to exceed 1 billion oral solid dose units. Catalent hopes the acquisition will strengthen their efforts to meet customer expectations in simplifying and accelerating development and manufacturing programs.  

Group President of Catalent’s Pharma & Consumer Health segment Aris Gennadios commented: “This acquisition will further expand Catalent’s ability to meet our customers’ expectations in fast-growing areas of the business and patient need. The experienced team and consistently improved, state-of-the-art facility in Greenville will provide Catalent’s customers with immediate, fit-for-scale capacity for in-demand highly potent drugs and other oral solid small-to-mid-size batch needs. This capacity is particularly important for customers with R&D pipelines featuring accelerated, orphan, and rare disease programs for oncology and other important therapeutic areas.” 

Scott Richards, CEO of Mayne Pharma, added: “Over the past several years, Metrics has undergone a period of transformational change to expand its footprint and service offering, becoming a global end-to-end novel oral solid CDMO. Catalent, a global leader in advanced drug development and manufacturing, is well-positioned to continue to invest in and accelerate the growth of Metrics and we believe this transaction will be extremely positive for our Greenville team and customers.” 

The acquisition is expected to be closed before the end of 2022, adding a team of over 400 employees to Catalent.  

Source: Catalent to Acquire Metrics Contract Services for $475 Million 

Vivian Xie
Editor - Custom Content

Related News